Interestingly, reduced SETD7 expression or inactivating mutations is significantly correlated with poor patient prognosis in multiple cancers (Akiyama et al., 2016). Recently, FBXO6 has been shown to affect the DNA damage, a process which promotes cell proliferation and survival in response to DNA damage (Zhang et al., 2009). Our data unify these observations and demonstrate that RIOK1 accumulation due to altered SETD7, LSD1, CK2, and FBXO6 expression provides an advantage in CRC and GC cells during disease progression. Here, SETD7 is linked to colorectal carcinoma.